注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Karyopharm Therapeutics Inc是一家商业阶段的制药公司。它专注于用于治疗癌症和其他疾病的核出口药物的发现、开发和营销业务。其选择性核输出抑制剂(SINE)化合物通过结合并抑制核输出蛋白XPO1(CRM1)发挥作用。其先导化合物XPOVIO(selinexor)与Velcade(硼替佐米)和地塞米松联合上市,用于治疗至少一种既往治疗后的成年多发性骨髓瘤患者;并作为治疗复发性或难治性弥漫性大B细胞淋巴瘤(DLBCL)成人患者的单一疗法。“NEXPOVIO”(selinexor)是XPOVIO在欧洲的品牌名称,与地塞米松联合用于治疗成人多发性骨髓瘤患者。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Garen G. Bohlin | 77 | 2013 | Independent Director |
Barry E. Greene | 61 | 2013 | Lead Independent Director |
Deepika Rachel Pakianathan | 59 | 2013 | Independent Director |
Michael R. Savona | - | - | Member of Scientific Advisory Board |
Richard A. Paulson | 57 | 2020 | President, CEO & Director |
Zhen Su | - | 2023 | Independent Director |
Andrew B. Lassman | - | 2020 | Member of Scientific Advisory Board |
Christy J. Oliger | 54 | 2020 | Independent Director |
Chen Schor | 52 | 2020 | Independent Director |
Andrew Kung | - | 2020 | Member of Scientific Advisory Board |
Sharon Shacham | 54 | 2008 | Co-Founder & Chairman of Scientific Advisory Board |
Mansoor Raza Mirza | 63 | 2010 | Clinical Consultant, Member of Scientific Advisory Board & Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核